Celgene/Agios Team Up In Long-Term Cancer Metabolism Pact

Agios will receive $130 million upfront, while Celgene gains the option to develop any drugs resulting from the biotech's cancer metabolism research platform for an undisclosed period of time.

More from Archive

More from Pink Sheet